Mutation-specific therapies in cystic fibrosis:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English |
| Veröffentlicht: |
Bremen
UNI-MED Verlag AG
2022
|
| Ausgabe: | 2nd edition |
| Schriftenreihe: | UNI-MED Science
|
| Schlagworte: | |
| Online-Zugang: | Inhaltstext Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | 128 Seiten Illustrationen 24.5 cm x 17.5 cm, 392 g |
| ISBN: | 9783837416305 3837416305 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV048625798 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 221228s2022 a||| |||| 00||| eng d | ||
| 015 | |a 22,N21 |2 dnb | ||
| 016 | 7 | |a 1258090783 |2 DE-101 | |
| 020 | |a 9783837416305 |c Festeinband : EUR 44.80 (DE), EUR 46.10 (AT), CHF 74.00 (freier Preis) |9 978-3-8374-1630-5 | ||
| 020 | |a 3837416305 |9 3-8374-1630-5 | ||
| 024 | 3 | |a 9783837416305 | |
| 035 | |a (OCoLC)1319838407 | ||
| 035 | |a (DE-599)DNB1258090783 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 | ||
| 084 | |a 610 |2 sdnb | ||
| 100 | 1 | |a Tümmler, Burkhard |d 1952- |e Verfasser |0 (DE-588)131336797 |4 aut | |
| 245 | 1 | 0 | |a Mutation-specific therapies in cystic fibrosis |c Burkhard Tümmler ; in collaboration with [27 others] |
| 250 | |a 2nd edition | ||
| 264 | 1 | |a Bremen |b UNI-MED Verlag AG |c 2022 | |
| 300 | |a 128 Seiten |b Illustrationen |c 24.5 cm x 17.5 cm, 392 g | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 0 | |a UNI-MED Science | |
| 650 | 0 | 7 | |a Mutation |0 (DE-588)4170883-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Therapie |0 (DE-588)4059798-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Mukoviszidose |0 (DE-588)4040669-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a CFTR |0 (DE-588)7752632-6 |2 gnd |9 rswk-swf |
| 653 | |a Mutation-specific therapies | ||
| 653 | |a cystic fibrosis | ||
| 653 | |a therapy | ||
| 689 | 0 | 0 | |a CFTR |0 (DE-588)7752632-6 |D s |
| 689 | 0 | 1 | |a Mutation |0 (DE-588)4170883-0 |D s |
| 689 | 0 | 2 | |a Mukoviszidose |0 (DE-588)4040669-6 |D s |
| 689 | 0 | 3 | |a Therapie |0 (DE-588)4059798-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 710 | 2 | |a UNI-MED Verlag AG |0 (DE-588)1065561733 |4 pbl | |
| 780 | 0 | 0 | |i Vorangegangen ist |z 9783837414769 |
| 856 | 4 | 2 | |m X:MVB |q text/html |u http://deposit.dnb.de/cgi-bin/dokserv?id=0312c983300245d5a76c10dfb9675591&prov=M&dok_var=1&dok_ext=htm |3 Inhaltstext |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u http://digitale-objekte.hbz-nrw.de/storage2/2022/09/15/file_24/9256652.pdf |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034000921&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-034000921 | ||
Datensatz im Suchindex
| _version_ | 1804184752962404352 |
|---|---|
| adam_text | CONTENTS
CFTR
AND
CYSTIC
FIBROSIS
13
1.1.
TO
SET
THE
STAGE:
CYSTIC
FIBROSIS
-
ETIOLOGY
AND
SIGNIFICANCE
........................................................
13
1.2.
THE
MOLECULAR
STRUCTURES
OF
CFTR
..................................................................................................
13
1.2.1.
CFTR
IS
AN
UNUSUAL
ABC
TRANSPORTER
AND
AN
UNUSUAL
ION
CHANNEL
.....................................................
14
1.2.2.
STRUCTURE
OF
THE
NON-PHOSPHORYLATED
CFTR
.......................................................................................
15
1.2.3.
STRUCTURE
OF
PHOSPHORYLATED
CFTR
IN
COMPLEX
WITH
ATP
..................................................................
16
1.2.4.
CONFORMATIONAL
CHANGES
LEADING
TO
CHANNEL
OPENING
.....................................................................
16
1.2.5.
THETM
HINGE
AS
A
HOTSPOT
FOR
CFTR
POTENTIATION
.............................................................................
17
1.3.
FEATURES
OF
CFTR:
AN
EPITHELIAL
ANION
CHANNEL
WITH
COMPLEX
REGULATION
...................................
19
1.3.1.
THE
FUNCTIONAL
ARCHITECTURE
OF
CFTR
..................................................................................................
19
1.3.2.
PHOSPHORYLATION-DEPENDENT
REGULATION
OF
CFTR:
THE
RD
..................................................................
19
1.3.3.
REGULATION
OF
CFTR
CHANNEL
GATING
BY
ATP
BINDING
AND
HYDROLYSIS:
THE
NBDS
.................................
20
1.3.4.
ANION
FLOW
THROUGH
THE
CFTR
PORE:
THE
MSDS
..................................................................................
21
1.3.5.
STRUCTURAL
REARRANGEMENTS
OF
CFTR
DOMAINS
DURING
CHANNEL
GATING
................................................
22
1.4.
BASIC
DEFECT
IN
CYSTIC
FIBROSIS
............................................................................................................
23
1.4.1.
CF
MUTATIONS
CAUSE
MOLECULAR
DEFECTS
IN
THE
CFTR
CI
CHANNEL
........................................................
24
1.4.2.
CF-ASSOCIATED
MUTATIONS
CAUSE
DEFICITS
OF
CFTR
FUNCTION
.................................................................
25
1.4.3.
FUNCTIONAL
DEFICITS
OF
CFTR
MUTANTS
LEAD
TO
DEFECTS
IN
EPITHELIAL
FUNCTION
........................................
25
1.4.4.
CFTR
DYSFUNCTION
CAUSES
DEFECTS
IN
NON-EPITHELIAL
TISSUES................................................................
26
1.5.
POPULATION
GENETICS
OF
CFTR
MUTATIONS
........................................................................................
26
1.6.
MOLECULAR
PATHOLOGY
OF
CFTR
MUTATIONS
......................................................................................
33
1.6.1.
DELETIONS,
FRAME-SHIFT
MUTATIONS
AND
STOP
MUTATIONS
......................................................................
33
1.6.2.
SPLICE
MUTATIONS
...............................................................................................................................
34
1.6.3.
MISSENSE
MUTATIONS
..........................................................................................................................
34
1.6.4.
THE
MAJOR
MUTATION
P.PHE508DEL
.....................................................................................................
34
1.7.
REFERENCES
........................................................................................................................................
35
BIOASSAYS
TO
ASSESS
CFTR
FUNCTION
IN
HUMANS
43
2.1.
SWEAT
CHLORIDE
TEST
AND
P-ADRENERGIC
SWEAT
SECRETION
................................................................
43
2.2.
NASAL
TRANSEPITHELIAL
POTENTIAL
DIFFERENCE
MEASUREMENTS
...........................................................
45
2.2.1.
BACKGROUND
.......................................................................................................................................
45
2.2.2.
PRINCIPLE
OF
THE
ASSAY........................................................................................................................
45
2.2.3.
APPLICATIONS
.....................................................................................................................................
46
2.3.
INTESTINAL
CURRENT
MEASUREMENTS
..................................................................................................47
2.3.1.
PRINCIPLE
OF
THE
ASSAY........................................................................................................................
47
2.3.2.
APPLICATIONS
.....................................................................................................................................
48
2.4.
PRIMARY
CYSTIC
FIBROSIS
INTESTINAL
ORGANOIDS
...................................................................................
51
2.4.1.
WHAT
ARE
ORGANOIDS?
........................................................................................................................
51
2.4.2.
ORGANOID
SWELLING
AS
MEASURE
OF
TRANSEPITHELIAL
ION
TRANSPORT
........................................................
51
2.4.3.
EXPLORING
ORGANOIDS
AS
LIVING
BIOMARKER
..........................................................................................
54
2.5.
IMMUNOCHEMICAL
CFTR
PROTEIN
ANALYSIS
IN
PATIENTS
TISSUES
........................................................
55
2.6.
REFERENCES
........................................................................................................................................
56
DM
ENDPOINTS
OF
PHASE
II
AND
PHASE
III
TRIALS
WITH
CFTR
MODULATORS
65
3.1.
LUNG
FUNCTION
..................................................................................................................................
65
3.2.
IMAGING
............................................................................................................................................
66
3.3.
EXTRA-PULMONARY
ENDPOINTS
...........................................................................................................
69
3.4.
REFERENCES
.........................................................................................................................................
71
DM
CORRECTORS
OF
NONSENSE
MUTATIONS:
MOLECULAR
PRINCIPLES,
PRECLINICAL
AND
CLINICAL
TRIALS
77
4.1.
READ-THROUGH
OF
PREMATURE
TERMINATION
CODONS
.........................................................................
77
4.2.
NOVEL
DRUG
DEVELOPMENTS
...............................................................................................................
78
4.3.
THE
ROLE
OF
CFTR
MODULATORS
AS
A
THERAPEUTIC
APPROACH
FOR
CFTR
NONSENSE
MUTATIONS
...........
79
4.4.
VARIABILITY
IN
THE
RESPONSE
TO
READ-THROUGH
TREATMENT
................................................................
80
4.5.
NMD
AS
A
REGULATOR
OF
THE
RESPONSE
TO
READ-THROUGH
TREATMENT
...............................................
80
4.6.
UPR
AS
A
REGULATOR
OF
THE
RESPONSE
TO
READ-THROUGH
TREATMENT
.................................................
81
4.7.
REFERENCES
.........................................................................................................................................
83
U
CFTR
CORRECTORS
AND
CFTR
POTENTIATORS
89
5.1.
PRECLINICAL
STUDIES
............................................................................................................................
89
5.2.
CLINICAL
PHARMACOLOGY:
PHARMACOKINETICS,
METABOLISM
AND
DRUG-DRUG
INTERACTIONS
..............
92
5.2.1.
POLYPHARMACY
AND
CYSTIC
FIBROSIS
.....................................................................................................
92
5.2.2.
COMPARISON
OF
THE
CFTR
MODULATORS
................................................................................................
93
5.2.3.
PHARMACOKINETICS
OF
THE
CFTR
MODULATORS
.......................................................................................
93
5.2.3.1.
DISTRIBUTION
.........................................................................................................................................
93
5.23.2.
METABOLISM
.........................................................................................................................................
94
5.2.4.
IMPACT
OF
CYP-INHIBITORS
ON
IVACAFTOR
SERUM
LEVELS...........................................................................
94
5.2.5.
IMPACT
OF
LIVER
FUNCTION
......................................................................................................................
94
5.2.6.
INDUCERS
OF
THE
CYP-SYSTEM
...............................................................................................................
95
5.2.7.
TEZACAFTOR
AND
ELEXACAFTOR
-
NOVEL
AGENTS
WITH
LOWER
RISK
FOR
INTERACTIONS
......................................
95
5.3.
CLINICAL
TRIALS
.....................................................................................................................................
96
5.4.
POST-APPROVAL
STUDIES
....................................................................................................................
104
5.5.
REFERENCES
.....................................................................................................................................
107
DM
PERSPECTIVES
ON
MUTATION-SPECIFIC
DRUG
THERAPIES
FOR
CYSTIC
FIBROSIS
121
6.1.
REFERENCES
.....................................................................................................................................
124
ABBREVIATIONS
INDEX
127
128
|
| adam_txt |
CONTENTS
CFTR
AND
CYSTIC
FIBROSIS
13
1.1.
TO
SET
THE
STAGE:
CYSTIC
FIBROSIS
-
ETIOLOGY
AND
SIGNIFICANCE
.
13
1.2.
THE
MOLECULAR
STRUCTURES
OF
CFTR
.
13
1.2.1.
CFTR
IS
AN
UNUSUAL
ABC
TRANSPORTER
AND
AN
UNUSUAL
ION
CHANNEL
.
14
1.2.2.
STRUCTURE
OF
THE
NON-PHOSPHORYLATED
CFTR
.
15
1.2.3.
STRUCTURE
OF
PHOSPHORYLATED
CFTR
IN
COMPLEX
WITH
ATP
.
16
1.2.4.
CONFORMATIONAL
CHANGES
LEADING
TO
CHANNEL
OPENING
.
16
1.2.5.
THETM
HINGE
AS
A
HOTSPOT
FOR
CFTR
POTENTIATION
.
17
1.3.
FEATURES
OF
CFTR:
AN
EPITHELIAL
ANION
CHANNEL
WITH
COMPLEX
REGULATION
.
19
1.3.1.
THE
FUNCTIONAL
ARCHITECTURE
OF
CFTR
.
19
1.3.2.
PHOSPHORYLATION-DEPENDENT
REGULATION
OF
CFTR:
THE
RD
.
19
1.3.3.
REGULATION
OF
CFTR
CHANNEL
GATING
BY
ATP
BINDING
AND
HYDROLYSIS:
THE
NBDS
.
20
1.3.4.
ANION
FLOW
THROUGH
THE
CFTR
PORE:
THE
MSDS
.
21
1.3.5.
STRUCTURAL
REARRANGEMENTS
OF
CFTR
DOMAINS
DURING
CHANNEL
GATING
.
22
1.4.
BASIC
DEFECT
IN
CYSTIC
FIBROSIS
.
23
1.4.1.
CF
MUTATIONS
CAUSE
MOLECULAR
DEFECTS
IN
THE
CFTR
CI
CHANNEL
.
24
1.4.2.
CF-ASSOCIATED
MUTATIONS
CAUSE
DEFICITS
OF
CFTR
FUNCTION
.
25
1.4.3.
FUNCTIONAL
DEFICITS
OF
CFTR
MUTANTS
LEAD
TO
DEFECTS
IN
EPITHELIAL
FUNCTION
.
25
1.4.4.
CFTR
DYSFUNCTION
CAUSES
DEFECTS
IN
NON-EPITHELIAL
TISSUES.
26
1.5.
POPULATION
GENETICS
OF
CFTR
MUTATIONS
.
26
1.6.
MOLECULAR
PATHOLOGY
OF
CFTR
MUTATIONS
.
33
1.6.1.
DELETIONS,
FRAME-SHIFT
MUTATIONS
AND
STOP
MUTATIONS
.
33
1.6.2.
SPLICE
MUTATIONS
.
34
1.6.3.
MISSENSE
MUTATIONS
.
34
1.6.4.
THE
MAJOR
MUTATION
P.PHE508DEL
.
34
1.7.
REFERENCES
.
35
BIOASSAYS
TO
ASSESS
CFTR
FUNCTION
IN
HUMANS
43
2.1.
SWEAT
CHLORIDE
TEST
AND
P-ADRENERGIC
SWEAT
SECRETION
.
43
2.2.
NASAL
TRANSEPITHELIAL
POTENTIAL
DIFFERENCE
MEASUREMENTS
.
45
2.2.1.
BACKGROUND
.
45
2.2.2.
PRINCIPLE
OF
THE
ASSAY.
45
2.2.3.
APPLICATIONS
.
46
2.3.
INTESTINAL
CURRENT
MEASUREMENTS
.47
2.3.1.
PRINCIPLE
OF
THE
ASSAY.
47
2.3.2.
APPLICATIONS
.
48
2.4.
PRIMARY
CYSTIC
FIBROSIS
INTESTINAL
ORGANOIDS
.
51
2.4.1.
WHAT
ARE
ORGANOIDS?
.
51
2.4.2.
ORGANOID
SWELLING
AS
MEASURE
OF
TRANSEPITHELIAL
ION
TRANSPORT
.
51
2.4.3.
EXPLORING
ORGANOIDS
AS
LIVING
BIOMARKER
.
54
2.5.
IMMUNOCHEMICAL
CFTR
PROTEIN
ANALYSIS
IN
PATIENTS'
TISSUES
.
55
2.6.
REFERENCES
.
56
DM
ENDPOINTS
OF
PHASE
II
AND
PHASE
III
TRIALS
WITH
CFTR
MODULATORS
65
3.1.
LUNG
FUNCTION
.
65
3.2.
IMAGING
.
66
3.3.
EXTRA-PULMONARY
ENDPOINTS
.
69
3.4.
REFERENCES
.
71
DM
CORRECTORS
OF
NONSENSE
MUTATIONS:
MOLECULAR
PRINCIPLES,
PRECLINICAL
AND
CLINICAL
TRIALS
77
4.1.
READ-THROUGH
OF
PREMATURE
TERMINATION
CODONS
.
77
4.2.
NOVEL
DRUG
DEVELOPMENTS
.
78
4.3.
THE
ROLE
OF
CFTR
MODULATORS
AS
A
THERAPEUTIC
APPROACH
FOR
CFTR
NONSENSE
MUTATIONS
.
79
4.4.
VARIABILITY
IN
THE
RESPONSE
TO
READ-THROUGH
TREATMENT
.
80
4.5.
NMD
AS
A
REGULATOR
OF
THE
RESPONSE
TO
READ-THROUGH
TREATMENT
.
80
4.6.
UPR
AS
A
REGULATOR
OF
THE
RESPONSE
TO
READ-THROUGH
TREATMENT
.
81
4.7.
REFERENCES
.
83
U
CFTR
CORRECTORS
AND
CFTR
POTENTIATORS
89
5.1.
PRECLINICAL
STUDIES
.
89
5.2.
CLINICAL
PHARMACOLOGY:
PHARMACOKINETICS,
METABOLISM
AND
DRUG-DRUG
INTERACTIONS
.
92
5.2.1.
POLYPHARMACY
AND
CYSTIC
FIBROSIS
.
92
5.2.2.
COMPARISON
OF
THE
CFTR
MODULATORS
.
93
5.2.3.
PHARMACOKINETICS
OF
THE
CFTR
MODULATORS
.
93
5.2.3.1.
DISTRIBUTION
.
93
5.23.2.
METABOLISM
.
94
5.2.4.
IMPACT
OF
CYP-INHIBITORS
ON
IVACAFTOR
SERUM
LEVELS.
94
5.2.5.
IMPACT
OF
LIVER
FUNCTION
.
94
5.2.6.
INDUCERS
OF
THE
CYP-SYSTEM
.
95
5.2.7.
TEZACAFTOR
AND
ELEXACAFTOR
-
NOVEL
AGENTS
WITH
LOWER
RISK
FOR
INTERACTIONS
.
95
5.3.
CLINICAL
TRIALS
.
96
5.4.
POST-APPROVAL
STUDIES
.
104
5.5.
REFERENCES
.
107
DM
PERSPECTIVES
ON
MUTATION-SPECIFIC
DRUG
THERAPIES
FOR
CYSTIC
FIBROSIS
121
6.1.
REFERENCES
.
124
ABBREVIATIONS
INDEX
127
128 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author | Tümmler, Burkhard 1952- |
| author_GND | (DE-588)131336797 |
| author_facet | Tümmler, Burkhard 1952- |
| author_role | aut |
| author_sort | Tümmler, Burkhard 1952- |
| author_variant | b t bt |
| building | Verbundindex |
| bvnumber | BV048625798 |
| ctrlnum | (OCoLC)1319838407 (DE-599)DNB1258090783 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| edition | 2nd edition |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02300nam a2200541 c 4500</leader><controlfield tag="001">BV048625798</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">221228s2022 a||| |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">22,N21</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1258090783</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783837416305</subfield><subfield code="c">Festeinband : EUR 44.80 (DE), EUR 46.10 (AT), CHF 74.00 (freier Preis)</subfield><subfield code="9">978-3-8374-1630-5</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3837416305</subfield><subfield code="9">3-8374-1630-5</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783837416305</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1319838407</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1258090783</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tümmler, Burkhard</subfield><subfield code="d">1952-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)131336797</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Mutation-specific therapies in cystic fibrosis</subfield><subfield code="c">Burkhard Tümmler ; in collaboration with [27 others]</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">2nd edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Bremen</subfield><subfield code="b">UNI-MED Verlag AG</subfield><subfield code="c">2022</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">128 Seiten</subfield><subfield code="b">Illustrationen</subfield><subfield code="c">24.5 cm x 17.5 cm, 392 g</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">UNI-MED Science</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Mutation</subfield><subfield code="0">(DE-588)4170883-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Mukoviszidose</subfield><subfield code="0">(DE-588)4040669-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">CFTR</subfield><subfield code="0">(DE-588)7752632-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Mutation-specific therapies</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cystic fibrosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">therapy</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">CFTR</subfield><subfield code="0">(DE-588)7752632-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Mutation</subfield><subfield code="0">(DE-588)4170883-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Mukoviszidose</subfield><subfield code="0">(DE-588)4040669-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Therapie</subfield><subfield code="0">(DE-588)4059798-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">UNI-MED Verlag AG</subfield><subfield code="0">(DE-588)1065561733</subfield><subfield code="4">pbl</subfield></datafield><datafield tag="780" ind1="0" ind2="0"><subfield code="i">Vorangegangen ist</subfield><subfield code="z">9783837414769</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">X:MVB</subfield><subfield code="q">text/html</subfield><subfield code="u">http://deposit.dnb.de/cgi-bin/dokserv?id=0312c983300245d5a76c10dfb9675591&prov=M&dok_var=1&dok_ext=htm</subfield><subfield code="3">Inhaltstext</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://digitale-objekte.hbz-nrw.de/storage2/2022/09/15/file_24/9256652.pdf</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034000921&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034000921</subfield></datafield></record></collection> |
| id | DE-604.BV048625798 |
| illustrated | Illustrated |
| index_date | 2024-07-03T21:15:01Z |
| indexdate | 2024-07-10T09:44:20Z |
| institution | BVB |
| institution_GND | (DE-588)1065561733 |
| isbn | 9783837416305 3837416305 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034000921 |
| oclc_num | 1319838407 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM |
| owner_facet | DE-19 DE-BY-UBM |
| physical | 128 Seiten Illustrationen 24.5 cm x 17.5 cm, 392 g |
| publishDate | 2022 |
| publishDateSearch | 2022 |
| publishDateSort | 2022 |
| publisher | UNI-MED Verlag AG |
| record_format | marc |
| series2 | UNI-MED Science |
| spelling | Tümmler, Burkhard 1952- Verfasser (DE-588)131336797 aut Mutation-specific therapies in cystic fibrosis Burkhard Tümmler ; in collaboration with [27 others] 2nd edition Bremen UNI-MED Verlag AG 2022 128 Seiten Illustrationen 24.5 cm x 17.5 cm, 392 g txt rdacontent n rdamedia nc rdacarrier UNI-MED Science Mutation (DE-588)4170883-0 gnd rswk-swf Therapie (DE-588)4059798-2 gnd rswk-swf Mukoviszidose (DE-588)4040669-6 gnd rswk-swf CFTR (DE-588)7752632-6 gnd rswk-swf Mutation-specific therapies cystic fibrosis therapy CFTR (DE-588)7752632-6 s Mutation (DE-588)4170883-0 s Mukoviszidose (DE-588)4040669-6 s Therapie (DE-588)4059798-2 s DE-604 UNI-MED Verlag AG (DE-588)1065561733 pbl Vorangegangen ist 9783837414769 X:MVB text/html http://deposit.dnb.de/cgi-bin/dokserv?id=0312c983300245d5a76c10dfb9675591&prov=M&dok_var=1&dok_ext=htm Inhaltstext B:DE-101 application/pdf http://digitale-objekte.hbz-nrw.de/storage2/2022/09/15/file_24/9256652.pdf Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034000921&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Tümmler, Burkhard 1952- Mutation-specific therapies in cystic fibrosis Mutation (DE-588)4170883-0 gnd Therapie (DE-588)4059798-2 gnd Mukoviszidose (DE-588)4040669-6 gnd CFTR (DE-588)7752632-6 gnd |
| subject_GND | (DE-588)4170883-0 (DE-588)4059798-2 (DE-588)4040669-6 (DE-588)7752632-6 |
| title | Mutation-specific therapies in cystic fibrosis |
| title_auth | Mutation-specific therapies in cystic fibrosis |
| title_exact_search | Mutation-specific therapies in cystic fibrosis |
| title_exact_search_txtP | Mutation-specific therapies in cystic fibrosis |
| title_full | Mutation-specific therapies in cystic fibrosis Burkhard Tümmler ; in collaboration with [27 others] |
| title_fullStr | Mutation-specific therapies in cystic fibrosis Burkhard Tümmler ; in collaboration with [27 others] |
| title_full_unstemmed | Mutation-specific therapies in cystic fibrosis Burkhard Tümmler ; in collaboration with [27 others] |
| title_short | Mutation-specific therapies in cystic fibrosis |
| title_sort | mutation specific therapies in cystic fibrosis |
| topic | Mutation (DE-588)4170883-0 gnd Therapie (DE-588)4059798-2 gnd Mukoviszidose (DE-588)4040669-6 gnd CFTR (DE-588)7752632-6 gnd |
| topic_facet | Mutation Therapie Mukoviszidose CFTR |
| url | http://deposit.dnb.de/cgi-bin/dokserv?id=0312c983300245d5a76c10dfb9675591&prov=M&dok_var=1&dok_ext=htm http://digitale-objekte.hbz-nrw.de/storage2/2022/09/15/file_24/9256652.pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=034000921&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT tummlerburkhard mutationspecifictherapiesincysticfibrosis AT unimedverlagag mutationspecifictherapiesincysticfibrosis |